What You Should Know:–  Cognizant (Nasdaq: CTSH) announced an expanded agreement with Medidata, a Dassault Systèmes brand and leader of clinical trial solutions to the life sciences industry, to provide support for Medidata’s life sciences clients and expand the strategic alliance partnership. –  Over the years, the companies have partnered to deliver a comprehensive framework supporting life sciences clients, emphasizing customer success, patient service desk, implementation, engineering, integrations, and user acceptance testing services using Medidata’s clinical platform and solutions. Cognizant and Medidata: Transforming Clinical Research Through AI-Powered InnovationCognizant (Nasdaq: CTSH) engineers modern businesses by helping clients modernize technology, reimagine processes, and transform experiences to stay ahead in a fast-changing world. In a renewed multi-year collaboration, Cognizant and Medidata aim to enhance responsiveness and improve user satisfaction for life sciences organizations relying on Medidata’s technology services for clinical trial development.·       Dedicated Medidata Platform Support: Cognizant provides a specialized team of Medidata Platform experts to assist pharmaceutical, biotech, medical device, and contract research organizations, as well as patients using Medidata services. This support maximizes Medidata’s value for life sciences clients, improving the overall user experience and enabling clients to focus on clinical trial development and patient outcomes.·       AI-Driven Clinical Trial Acceleration: The partnership expands access to Medidata’s AI-powered technologies, including Medidata Clinical Data Studio, Medidata Health Record Connect, and the myMedidata patient portal. These solutions streamline research and development by enhancing patient, site, and data experiences.·       Operational Excellence and Data Modernization: As a top Global Medidata Strategic Alliance Partner, Cognizant leverages its extensive network of Medidata Certified Services Professionals to help life sciences organizations modernize clinical operations and data management.“Our partnership with Cognizant represents a shared commitment to transforming clinical research through innovation and expertise,” said Janet Butler, EVP, Head of Global Sales, Medidata. “By combining Medidata’s advanced AI-driven technologies with Cognizant’s deep industry knowledge and operational excellence, we support life sciences organizations in streamlining their RD efforts, deriving actionable insights from complex data, and ultimately bringing life-changing therapies to patients more efficiently.”

AVIZVA, a health-tech organization that offers a variety of solutions for healthcare enterprises, that it has appoints James Vertino as its new CEO.Model N appoints Bret Connor as Chief Executive Officer. The Board of Directors of Blue Shield of California appoints Lois Quam as chief executive officer to lead Blue Shield of California, the first woman to serve as CEO in the health plan’s 86-year history. She joined the company as president in 2024.   Yaqrit, a late-stage biotech and medtech company developing lifesaving treatments for advanced liver diseases appoints Troels Jordansen has joined Yaqrit as Chief Executive Officer.OP Solutions names Michael Kallish as Chief Executive Officer, effective immediately.Access TeleCare appoints Dr. Michael Genovese to Chief Medical Officer for Behavioral Health.Enveda appoints Jason Kim as Chief Financial Officer (CFO).Eko Health appoints of Justin Spencer as Chief Financial Officer (CFO). (Pull from site)Qure.ai appoints Jim Mercadante as its new Chief Commercial Officer. (Pull from site)Symplr, appoints Dr

Medidata Platform Enhances Clinical Trial Efficiency for Bristol Myers Squibb. by Syed Hamza Sohail 01/08/2025 Leave a Comment. What You Should Know:– Medidata, a Dassault Systèmes brand and a leader in clinical trial solutions for the life sciences industry, has announced an extended and expanded partnership with Bristol Myers Squibb (BMS).–  This collaboration aims to enhance clinical research processes, improve patient outcomes, and foster advancements in personalized healthcare. Medidata and Bristol Myers Squibb Strengthen Partnership to Advance Clinical Research and Personalized Healthcare As part of the agreement, Bristol Myers Squibb will continue utilizing the Medidata Platform while exploring additional capabilities within Medidata’s suite of products. These include: – AI and advanced analytics to derive deeper insights from clinical trial data. – Innovative data management solutions to streamline trial operations. – The Medidata Clinical Data Studio, a newly launched tool designed to manage, monitor, and analyze clinical trials effectively. This strategic partnership extension will enable Bristol Myers Squibb to strengthen engagement with trial sites and patients, optimize processes, and accelerate the delivery of life-changing therapies to those in need. By leveraging cutting-edge technology, both organizations aim to set new benchmarks in clinical research and personalized treatment development